Tvardi Therapeutics (NASDAQ:TVRD) Stock Rating Lowered by Wall Street Zen

Tvardi Therapeutics (NASDAQ:TVRD) was downgraded by analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a research note issued to investors on Saturday, Wall Street Zen reports.

A number of other brokerages have also weighed in on TVRD. BTIG Research lowered their target price on Tvardi Therapeutics to $5.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. Raymond James Financial upgraded Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 price target for the company in a research note on Wednesday, July 8th. Piper Sandler raised Tvardi Therapeutics from a “neutral” rating to an “overweight” rating and set a $13.00 price objective on the stock in a report on Wednesday, July 8th. Lucid Cap Mkts upgraded Tvardi Therapeutics to a “strong-buy” rating in a research report on Tuesday, September 8th. Finally, HC Wainwright started coverage on Tvardi Therapeutics in a report on Monday, June 8th. They set a “buy” rating and a $9.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $18.00.

Tvardi Therapeutics Stock Performance

Shares of TVRD opened at $1.27 on Friday. The firm has a market cap of $16.94 million, a P/E ratio of -0.46 and a beta of 0.32. Tvardi Therapeutics has a 52 week low of $0.93 and a 52 week high of $43.65. The firm’s 50-day simple moving average is $1.92 and its 200 day simple moving average is $2.73.

Tvardi Therapeutics (NASDAQ:TVRD) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.04). As a group, equities analysts forecast that Tvardi Therapeutics will post -2.35 earnings per share for the current year.

Institutional Investors Weigh In On Tvardi Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. acquired a new position in Tvardi Therapeutics in the 2nd quarter valued at $181,000. Susquehanna International Group LLP acquired a new stake in shares of Tvardi Therapeutics during the 2nd quarter worth $63,000. Finally, GSA Capital Partners LLP acquired a new stake in shares of Tvardi Therapeutics during the 2nd quarter worth $34,000. 44.66% of the stock is currently owned by institutional investors and hedge funds.

Tvardi Therapeutics Company Profile

Tvardi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for cancer and other serious diseases driven by abnormal STAT3 signaling. The company’s approach is designed to address tumor growth, immune suppression and resistance to existing therapies by selectively targeting STAT3, a protein involved in cancer progression.

Tvardi’s lead product candidate is TTI-101, an orally administered small-molecule STAT3 inhibitor being evaluated in clinical studies for advanced solid tumors.